title: Prerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective.
abstract: Realizing that 60% to 80% of dopaminergic nigrostriatal neurons are nonfunctional at the time of clinical diagnosis, there is an emerging consensus that disease-modifying treatments should be initiated in the earliest stages of Parkinson's disease (PD). To date, clinical trial designs and metrics in PD have been focused on motor symptoms as the core feature of the clinical disease. To identify earlier or "pre-motor" populations in PD, new markers have been proposed. We address the prerequisites needed to use these pre-motor markers in clinical trials for the selection of subjects, definition of populations, and monitoring of disease progression. This may require the development of new diagnostic criteria potentially based on non-motor clinical signs, imaging techniques, or biological features, all requiring discussion in a regulatory framework. Questions addressed include: Which steps must be taken to gain a broad consensus in the field from academic opinion leaders, patient advocacy groups, regulatory bodies, and industry? How do we prevent the selection of subgroups, which may not be representative of the full disease spectrum? Is there a way forward in personalized medicine? How do we balance risk and benefit in an at-risk population? While many tools are available, a concerted effort is required to develop integrated data sets, as well as to achieve the necessary standardization for multicenter clinical trials. To this end, public-private consortia (including academic centers, patient advocacy groups, and industry) will be of crucial importance to prospectively investigate and define the best tools and treatment paradigms.
authors.affiliation: Janssen Research & Development, Janssen-Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium. jstreffe@its.jnj.com
authors.forename: Johannes R
authors.initials: JR
authors.lastname: Streffer
authors.forename: Igor D
authors.initials: ID
authors.lastname: Grachev
authors.forename: Cheryl
authors.initials: C
authors.lastname: Fitzer-Attas
authors.forename: Baltazar
authors.initials: B
authors.lastname: Gomez-Mancilla
authors.forename: Babak
authors.initials: B
authors.lastname: Boroojerdi
authors.forename: Juliana
authors.initials: J
authors.lastname: Bronzova
authors.forename: Susanne
authors.initials: S
authors.lastname: Ostrowitzki
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Victor
authors.forename: Paulo
authors.initials: P
authors.lastname: Fontoura
authors.forename: Robert
authors.initials: R
authors.lastname: Alexander
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D002986:Clinical Trials as Topic / Q000592:standards*; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000175:diagnosis / Q000378:metabolism / Q000517:prevention & control*; D012107:Research Design / Q000592:standards*
chemical_list: D015415:Biomarkers; D018696:Neuroprotective Agents